A new industry-focused piece lays out decision-making steps for accelerating the lab-to-clinic transition when moving an injectable molecule into humans. The guidance centers on how drug owners should coordinate batch planning, manufacturability, and regulatory readiness rather than optimizing solely for speed. Key areas include mapping the sequence of development decisions that connect primary packaging choices to material requirements, QbD design space, analytical methods, control strategies, and IND documentation. It also emphasizes formulation development questions that address scale-up feasibility of excipients and compounding steps, plus early communication of product vulnerabilities like light and temperature sensitivity. The article frames partnering with a CDMO as a way to align packaging, formulation, and GMP-scale constraints into a coherent pathway for a released clinical batch, reducing avoidable delays once trials begin.